NCT02196844 is a NA clinical trial of Hatha Yoga in Lung Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT02196844?

NCT02196844 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02196844?

Interventions in NCT02196844: Hatha Yoga, Questionnaires, Walk Test.

What condition does NCT02196844 study?

NCT02196844 studies Lung Cancer.

Is NCT02196844 still recruiting?

NCT02196844 is currently completed. Last updated 16 February 2023.

Last reviewed 2023-02-16 · How we verify

NCT02196844

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Yoga Program for Lung Cancer Patients and Caregivers

Completed NA Last updated 16 February 2023

What this trial tests

NA trial testing Hatha Yoga in Lung Cancer in 64 participants. Completed in 2 February 2023.

Timeline

29 September 2014

Primary endpoint
2 February 2023

2 February 2023

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	64
Start date	29 September 2014
Primary completion	2 February 2023
Estimated completion	2 February 2023
Sites	1 location across United States

Drugs / interventions tested

Hatha Yoga
Questionnaires
Walk Test

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this behavioral research study is to learn the opinion of patients and their caregivers about a couple-based Hatha Yoga program (Group 1) during treatment for cancer. Researchers also want to learn the effect of this program on lung function, distress, biological function, and quality of life. For comparison purposes, there will also be a group of participants (Group 2) that does not take part in this program. You and your caregiver/family member will have about a 50/50 chance of being assigned to each group. The groups are randomly assigned, but it is also based on other factors such as your age and the status of the disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Dyadic yoga program for patients undergoing thoracic radiotherapy and their family caregivers: Results of a pilot randomized controlled trial.
Milbury K, Liao Z, Shannon V, Mallaiah S, et al · · 2019 · cited 27× · PMID 30659739 · DOI 10.1002/pon.4991

Verify or expand the search:

Other trials of Hatha Yoga

Trials testing the same drug.

NCT07362771 — Effectiveness of Hatha Yoga With and Without Zumba Exercise on Clinical Outcomes in Females With Poly Cystic Ovarian Syn · NA · completed
NCT05336123 — The Peace of Mind and Body Project: Treatment Development of Yoga for Anger Management in Incarcerated Adults · NA · completed
NCT05377073 — Effects of Complementary Therapies in People With Mild to Moderate Parkinson's Disease · NA · completed
NCT03831347 — Treatments for Improving Mood in Depressed Teens-2 · NA · completed
NCT06497400 — Brazilian Jiu Jitsu vs. Yoga for Treating Symptoms of PTSD · NA · completed

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02196844 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 16 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02196844.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing